Coherus BioSciences (NASDAQ:CHRS) Rating Reiterated by HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $12.00 price target on the biotechnology company’s stock.

Several other equities analysts have also commented on CHRS. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research note on Friday, September 6th. UBS Group downgraded shares of Coherus BioSciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $4.00 to $1.50 in a research report on Friday, August 16th. Finally, Robert W. Baird reduced their price target on shares of Coherus BioSciences from $9.00 to $8.00 and set an “outperform” rating for the company in a research report on Monday, July 1st. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Coherus BioSciences currently has an average rating of “Moderate Buy” and an average target price of $6.92.

Coherus BioSciences Trading Down 1.0 %

Coherus BioSciences stock opened at $1.04 on Monday. The company has a fifty day simple moving average of $1.43 and a 200-day simple moving average of $1.82. The stock has a market cap of $119.32 million, a P/E ratio of -1.33 and a beta of 0.66. Coherus BioSciences has a 12-month low of $1.01 and a 12-month high of $4.91.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The business had revenue of $64.98 million for the quarter, compared to analysts’ expectations of $57.08 million. As a group, sell-side analysts forecast that Coherus BioSciences will post -1.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Coherus BioSciences

A number of institutional investors and hedge funds have recently made changes to their positions in CHRS. Nisa Investment Advisors LLC grew its holdings in shares of Coherus BioSciences by 2,672.8% during the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock worth $36,000 after buying an additional 19,912 shares during the last quarter. TrinityPoint Wealth LLC purchased a new position in shares of Coherus BioSciences in the 4th quarter valued at approximately $40,000. TIAA Trust National Association acquired a new position in shares of Coherus BioSciences in the second quarter valued at approximately $47,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Coherus BioSciences by 66.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 21,426 shares of the biotechnology company’s stock worth $51,000 after purchasing an additional 8,546 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new stake in shares of Coherus BioSciences during the first quarter worth $56,000. 72.82% of the stock is owned by hedge funds and other institutional investors.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.